{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:13:21Z","timestamp":1788585201232,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41380-026-03465-y","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:29:27Z","timestamp":1770218967000},"page":"3188-3198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers"],"prefix":"10.1038","volume":"31","author":[{"given":"C\u00e9line","family":"Fournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e8le","family":"Buchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4594-8229","authenticated-orcid":false,"given":"Susanne","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"P\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-6190","authenticated-orcid":false,"given":"Bjoern","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Norcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pflieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Sewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-5135","authenticated-orcid":false,"given":"Andrea","family":"Greiter-Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-935X","authenticated-orcid":false,"given":"Basil","family":"Kuennecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-5584","authenticated-orcid":false,"given":"Christophe","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Holiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-6250","authenticated-orcid":false,"given":"Marius C.","family":"Hoener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"3465_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tips.2005.03.007","volume":"26","author":"L Lindemann","year":"2005","unstructured":"Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci. 2005;26:274\u201381.","journal-title":"Trends Pharmacol Sci"},{"key":"3465_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","volume":"324","author":"L Lindemann","year":"2008","unstructured":"Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324:948\u201356.","journal-title":"J Pharmacol Exp Ther"},{"key":"3465_CR3","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"B Borowsky","year":"2001","unstructured":"Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA. 2001;98:8966\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3465_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molmet.2015.09.015","volume":"5","author":"S Raab","year":"2016","unstructured":"Raab S, Wang HY, Uhles S, Cole N, Alvarez-Sanchez R, K\u00fcnnecke B, et al. Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Mol Metab. 2016;5:47\u201356.","journal-title":"Mol Metab"},{"key":"3465_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"FG Revel","year":"2013","unstructured":"Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18:543\u201356.","journal-title":"Mol Psychiatry"},{"key":"3465_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00441-009-0859-x","volume":"338","author":"J Ito","year":"2009","unstructured":"Ito J, Ito M, Nambu H, Fujikawa T, Tanaka K, Iwaasa H, et al. Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL\/6J mice. Cell Tissue Res. 2009;338:257\u201369.","journal-title":"Cell Tissue Res"},{"key":"3465_CR7","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/npp.2012.109","volume":"37","author":"FG Revel","year":"2012","unstructured":"Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, Andre CB, et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012;37:2580\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"3465_CR8","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA. 2011;108:8485\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3465_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D(2) Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019;371:1\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"3465_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2018.00279","volume":"9","author":"JF Liu","year":"2018","unstructured":"Liu JF, Li JX. TAAR1 in addiction: looking beyond the tip of the iceberg. Front Pharmacol. 2018;9:279.","journal-title":"Front Pharmacol"},{"key":"3465_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/bs.apha.2021.10.005","volume":"93","author":"R Wu","year":"2022","unstructured":"Wu R, Liu J, Li JX. Trace amine-associated receptor 1 and drug abuse. Adv Pharmacol. 2022;93:373\u2013401.","journal-title":"Adv Pharmacol"},{"key":"3465_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pnpbp.2015.05.014","volume":"63","author":"Y Pei","year":"2015","unstructured":"Pei Y, Mortas P, Hoener MC, Canales JJ. Selective activation of the trace amine-associated receptor 1 decreases cocaine\u2019s reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds. Prog Neuropsychopharmacol Biol Psychiatry. 2015;63:70\u201375.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3465_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14472-z","volume":"7","author":"A Asif-Malik","year":"2017","unstructured":"Asif-Malik A, Hoener MC, Canales JJ. Interaction between the trace amine-associated receptor 1 and the dopamine D(2) receptor controls cocaine\u2019s neurochemical actions. Sci Rep. 2017;7:13901.","journal-title":"Sci Rep"},{"key":"3465_CR14","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","volume":"25","author":"A Harmeier","year":"2015","unstructured":"Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, et al. Trace amine-associated receptor 1 activation silences GSK3beta signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25:2049\u201361.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3465_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10571-020-00792-8","volume":"40","author":"J Liu","year":"2020","unstructured":"Liu J, Wu R, Li JX. TAAR1 and psychostimulant addiction. Cell Mol Neurobiol. 2020;40:229\u201338.","journal-title":"Cell Mol Neurobiol"},{"key":"3465_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161\u201380.","journal-title":"Pharmacol Ther"},{"key":"3465_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14728222.2018.1480723","volume":"22","author":"MD Schwartz","year":"2018","unstructured":"Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018;22:513\u201326.","journal-title":"Expert Opin Ther Targets"},{"key":"3465_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776\u201386.","journal-title":"Arch Gen Psychiatry"},{"key":"3465_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EMP Poels","year":"2014","unstructured":"Poels EMP, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Darghama A, et al. Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr Res. 2014;152:325\u201332.","journal-title":"Schizophr Res"},{"key":"3465_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra073096","volume":"358","author":"RH Belmaker","year":"2008","unstructured":"Belmaker RH, Agam G. Mechanisms of disease: major depressive disorder. New Engl J Med. 2008;358:55\u201368.","journal-title":"New Engl J Med"},{"key":"3465_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.31887\/DCNS.2008.10.4\/gracagni","volume":"10","author":"G Racagni","year":"2008","unstructured":"Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 2008;10:385\u2013400.","journal-title":"Dialogues Clin Neurosci"},{"key":"3465_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/msj.20043","volume":"75","author":"S Sen","year":"2008","unstructured":"Sen S, Sanacora G. Major depression: emerging therapeutics. Mt Sinai J Med. 2008;75:204\u201325.","journal-title":"Mt Sinai J Med"},{"key":"3465_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00213-006-0405-4","volume":"187","author":"G Juckel","year":"2006","unstructured":"Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl). 2006;187:222\u20138.","journal-title":"Psychopharmacology (Berl)"},{"key":"3465_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.","journal-title":"BMC Psychiatry"},{"key":"3465_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/hup.2350","volume":"28","author":"S Mas","year":"2013","unstructured":"Mas S, Gass\u00f3 P, de Bobadilla RF, Arnaiz JA, Bernardo M, Lafuente A. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharm Clin. 2013;28:586\u201393.","journal-title":"Hum Psychopharm Clin"},{"key":"3465_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/sj.npp.1300710","volume":"30","author":"KA Dorph-Petersen","year":"2005","unstructured":"Dorph-Petersen KA, Pierri JN, Perel JM, Sun ZX, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30:1649\u201361.","journal-title":"Neuropsychopharmacology"},{"key":"3465_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","volume":"68","author":"BC Ho","year":"2011","unstructured":"Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes. Arch Gen Psychiat. 2011;68:128\u201337.","journal-title":"Arch Gen Psychiat"},{"key":"3465_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","volume":"72","author":"FG Revel","year":"2012","unstructured":"Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velazquez-Sanchez C, Sotnikova TD, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry. 2012;72:934\u201342.","journal-title":"Biol Psychiatry"},{"key":"3465_CR29","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.molmet.2024.101883","volume":"80","author":"N Dedic","year":"2024","unstructured":"Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sorensen J, Roostalu U, Vickers SP, et al. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. Mol Metab. 2024;80:101883.","journal-title":"Mol Metab"},{"key":"3465_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497\u2013506.","journal-title":"N Engl J Med"},{"key":"3465_CR31","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22:13185.","journal-title":"Int J Mol Sci"},{"key":"3465_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll CU, Koblan KS, Hopkins SC, Li Y, Heather D, Goldman R, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7:63.","journal-title":"NPJ Schizophr"},{"key":"3465_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ijnp\/pyad049","volume":"26","author":"R Agren","year":"2023","unstructured":"Agren R, Betari N, Saarinen M, Zeberg H, Svenningsson P, Sahlholm K. In vitro comparison of ulotaront (SEP-363856) and ralmitaront (RO6889450): two TAAR1 agonist candidate antipsychotics. Int J Neuropsychopharmacol. 2023;26:599\u2013606.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3465_CR34","unstructured":"Trussardi R, Iding H. Process for the preparation of chiral 2-aryl morpholines. WO2015086495A1 edn2015."},{"key":"3465_CR35","unstructured":"Galley G, Hoener M, Norcross R, Pflieger P. 5-Ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of TAAR1. WO2017157873A1 edn2017."},{"key":"3465_CR36","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/sj.npp.1301654","volume":"33","author":"JS Rodefer","year":"2008","unstructured":"Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology. 2008;33:2657\u201366.","journal-title":"Neuropsychopharmacology"},{"key":"3465_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mrm.21779","volume":"61","author":"A Bruns","year":"2009","unstructured":"Bruns A, K\u00fcnnecke B, Risterucci C, Moreau JL, von Kienlin M. Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in Rats. Magn Reson Med. 2009;61:1451\u20138.","journal-title":"Magn Reson Med"},{"key":"3465_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2015.02.032","volume":"112","author":"A Bruns","year":"2015","unstructured":"Bruns A, Mueggler T, K\u00fcnnecke B, Risterucci C, Prinssen EP, Wettstein JG, et al. Domain gauges: A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats. Neuroimage. 2015;112:70\u201385.","journal-title":"Neuroimage"},{"key":"3465_CR39","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","volume":"106","author":"A Bradaia","year":"2009","unstructured":"Bradaia A, Trube G, Stalder H, Norcross RD, Ozmen L, Wettstein JG, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci USA. 2009;106:20081\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3465_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.114.220194","volume":"352","author":"S Fowler","year":"2015","unstructured":"Fowler S, Kletzl H, Finel M, Manevski N, Schmid P, Tuerck D, et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352:358\u201367.","journal-title":"J Pharmacol Exp Ther"},{"key":"3465_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.117.015305","volume":"70","author":"RR Gainetdinov","year":"2018","unstructured":"Gainetdinov RR, Hoener MC, Berry MD. Trace amines and their receptors. Pharmacol Rev. 2018;70:549\u2013620.","journal-title":"Pharmacol Rev"},{"key":"3465_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1017\/S1740925X10000141","volume":"6","author":"S Zhang","year":"2010","unstructured":"Zhang S, Li B, Lovatt D, Xu J, Song D, Goldman SA, et al. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional serotonin-specific reuptake inhibitors. Neuron Glia Biol. 2010;6:113\u201325.","journal-title":"Neuron Glia Biol"},{"key":"3465_CR43","doi-asserted-by":"publisher","first-page":"109261","DOI":"10.1016\/j.drugalcdep.2021.109261","volume":"231","author":"C Synan","year":"2022","unstructured":"Synan C, Bowen C, Heal DJ, Froger-Colleaux C, Beardsley PM, Dedic N, et al. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend. 2022;231:109261.","journal-title":"Drug Alcohol Depend"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03465-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:02:58Z","timestamp":1779282178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03465-y","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CF, DB, SM, AP, BJ, RN, PP, SS, AGW, BK, CS, MM, MM, SH, IG and MCH are employees of F. Hoffmann-La Roche, Ltd. and may own stock or stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}